Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Nkarta (Nasdaq:NKTX), a clinical-stage biopharma developing engineered NK cell therapies for autoimmune diseases, will participate in the H.C.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Nkarta (Nasdaq:NKTX), a clinical-stage biopharma developing engineered NK cell therapies for autoimmune diseases, will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference.

On June 30 at 2 p.m. ET, President Nadir Mahmood will join a webcast fireside chat on Nkarta’s investigational CAR-NK therapy for B cell-mediated autoimmune diseases, with a replay available for about 90 days.

Argus Jun 26 session

+1.80% close to close 2.5x rel. volume Open Argus

Details

News Market Reaction – NKTX

On Jun 26, the day this news came out, NKTX closed 1.80% above the previous close. That session’s volume was 2.5x the stock’s average daily volume.

Data tracked by StockTitan Argus for the Jun 26 session.

Key Figures

Conference time: 2 p.m. ET Conference date: June 30 Webcast replay duration: 90 days

Conference time: 2 p.m. ET; Scheduled fireside chat at H.C. Wainwright Cell Therapy Virtual Conference
Conference date: June 30; Date of Nkarta’s fireside chat at the virtual conference
Webcast replay duration: 90 days; Replay of the fireside chat archived on Nkarta’s investor website

Historical Context

5 past events · Latest: May 12

5 events

May 12
Earnings update

24h Move

-6.7%

Quarterly results and NKX019 progress reported alongside long cash runway guidance.
Apr 15
Regulatory update

24h Move

+15.7%

FDA agreement enabling outpatient NKX019 dosing and broader autoimmune trial access.
Apr 09
Conference participation

24h Move

+1.3%

Needham healthcare conference fireside chat on CAR-NK for autoimmune indications.
Mar 25
Earnings update

24h Move

+0.5%

Full-year 2025 results and NKX019 dose escalation plus 2026 data timing.
Feb 27
Investor conferences

24h Move

+3.0%

March investor conference fireside chats with webcast and 90-day replay.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

natural killer (nk) cell therapies, car-nk cell therapy

2 terms

natural killer (nk) cell therapies medical

"a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies"

Natural killer (NK) cell therapies use a type of immune cell that can find and destroy diseased cells — such as cancer — either after being grown and boosted outside the body or after being modified to work better. Investors care because these therapies represent a growing class of targeted treatments with the potential for high clinical benefit and commercial value, but they also carry scientific and regulatory risk similar to other advanced biotechnologies.

car-nk cell therapy medical

"updates on the company’s investigational CAR-NK cell therapy to treat B cell-mediated"

CAR-NK cell therapy uses a patient's or donor immune cells called natural killer (NK) cells that are genetically equipped with a targeting receptor (CAR) to find and destroy cancer cells. Think of it as giving trained guard dogs a custom scent to track intruders; the approach can be faster to deploy and potentially safer than some other cell therapies. Investors care because successful CAR-NK programs can drive clinical trial milestones, regulatory approvals, and scalable product models that affect company value and future revenue.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

06/26/2026 - 08:45 AM EDT

SOUTH SAN FRANCISCO, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in next week’s H.C. Wainwright 4th Annual Cell Therapy Virtual Conference.

At 2 p.m. ET on Tuesday, June 30th, Nkarta President Nadir Mahmood will take part in a fireside chat to share updates on the company’s investigational CAR-NK cell therapy to treat B cell-mediated autoimmune diseases.

A simultaneous webcast of the discussion will be available on the investors section of Nkarta’s website, and a replay will be archived on the website for approximately 90 days.

About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for people living with autoimmune diseases. By harnessing the power of the innate immune system to eliminate pathogenic B cells driving the autoimmune response, Nkarta is advancing novel cell therapies engineered for deep therapeutic impact. The on-demand availability and outpatient dosing of our CAR-NK cells enables a broad population of patients with different autoimmune conditions to conveniently access NK cell therapy in community health settings. For more information, please visit the company’s website at www.nkartatx.com.

Nkarta Media/Investor Contact:
Nadir Mahmood
Nkarta, Inc.
nmahmood@nkartatx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Nkarta (NASDAQ:NKTX) announce about the H.C. Wainwright Cell Therapy Virtual Conference on June 30, 2026?

Nkarta announced it will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. According to Nkarta, President Nadir Mahmood will join a 2 p.m. ET fireside chat focused on its investigational CAR-NK cell therapy.

When is Nkarta’s (NKTX) fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference?

Nkarta’s fireside chat is scheduled for 2 p.m. ET on Tuesday, June 30. According to Nkarta, President Nadir Mahmood will provide updates on the company’s investigational CAR-NK cell therapy for B cell-mediated autoimmune diseases during this virtual conference session.

What topic will Nkarta (NKTX) discuss at the H.C. Wainwright Cell Therapy Virtual Conference?

Nkarta will share updates on its investigational CAR-NK cell therapy to treat B cell-mediated autoimmune diseases. According to Nkarta, President Nadir Mahmood will discuss this program during a 2 p.m. ET fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference.

How can investors watch Nkarta’s (NKTX) June 30, 2026 conference fireside chat?

Investors can watch Nkarta’s fireside chat via a simultaneous webcast available on the investors section of Nkarta’s website. According to Nkarta, the online stream will cover updates on its investigational CAR-NK therapy for B cell-mediated autoimmune diseases.

Will a replay of Nkarta’s (NASDAQ:NKTX) H.C. Wainwright conference webcast be available to investors?

Yes, a replay of Nkarta’s conference webcast will be archived on its website. According to Nkarta, the replay of President Nadir Mahmood’s June 30 fireside chat will remain accessible in the investors section for approximately 90 days after the event.

What type of therapies is Nkarta (NKTX) developing as highlighted in its H.C. Wainwright conference participation?

Nkarta is developing engineered natural killer (NK) cell therapies to treat autoimmune diseases. According to Nkarta, the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference fireside chat will focus on its investigational CAR-NK cell therapy for B cell-mediated autoimmune diseases.

Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference